David D. Chang, M.D., Ph.D.

Executive Vice President, Research & Development, and Chief Medical Officer

151006_Kite_Pharma_0214

Dr. Chang has an industry-leading track record of innovation in the field of oncology drug development.  From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology.  During this time, Dr. Chang spearheaded personalized therapy strategies that underlied the success of Vectibix® (panitumumab).  He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab) a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGIC™ (talimogene laherparepvec) a first-of-its-kind oncolytic immunotherapy, in melanoma.  Prior to joining Amgen, Dr. Chang held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles.  He obtained a B.S. degree in Biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University.  Dr. Chang completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.